Nebula Research & Development LLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Nebula Research & Development LLC lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 92.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,239 shares of the company's stock after buying an additional 17,400 shares during the period. Nebula Research & Development LLC's holdings in BridgeBio Pharma were worth $994,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BBIO. Steward Partners Investment Advisory LLC grew its holdings in shares of BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after purchasing an additional 472 shares during the last quarter. Sterling Capital Management LLC increased its position in BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after buying an additional 1,514 shares during the period. Avanza Fonder AB purchased a new stake in BridgeBio Pharma in the fourth quarter valued at approximately $181,000. First Bank & Trust acquired a new stake in shares of BridgeBio Pharma in the fourth quarter valued at approximately $205,000. Finally, Moss Adams Wealth Advisors LLC purchased a new position in shares of BridgeBio Pharma during the fourth quarter worth approximately $208,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 68,000 shares of BridgeBio Pharma stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $2,467,720.00. Following the completion of the transaction, the chief financial officer now owns 93,758 shares in the company, valued at approximately $3,402,477.82. The trade was a 42.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Andrea Ellis sold 30,000 shares of the company's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $34.05, for a total transaction of $1,021,500.00. Following the completion of the sale, the director now directly owns 12,000 shares in the company, valued at $408,600. This trade represents a 71.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,769,739 shares of company stock valued at $329,866,901 in the last quarter. 24.66% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $36.31 on Friday. The company has a market cap of $6.89 billion, a P/E ratio of -12.74 and a beta of 1.08. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47. The business has a fifty day moving average of $33.92 and a two-hundred day moving average of $30.47.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million for the quarter, compared to analysts' expectations of $4.04 million. Sell-side analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on BBIO shares. HC Wainwright upped their price target on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Citigroup increased their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday, March 24th. Scotiabank lifted their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Friday, February 21st. Finally, Redburn Atlantic began coverage on BridgeBio Pharma in a report on Monday, March 31st. They issued a "buy" rating and a $50.00 target price on the stock. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, BridgeBio Pharma presently has an average rating of "Moderate Buy" and a consensus price target of $53.00.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.